Watchful waiting vs. external beam radiation: 15-year data from a randomized trial

According to a report presented today at the annual meeting of the American Society for Radiation Oncology (ASTRO) in Miami Beach, Florida, men with localized prostate cancer who were treated 15 years ago with external beam radiation therapy had no significant survival benefit compared to men followed with watchful waiting.

How much hypofractionated IMRT is too much for localized prostate cancer?

A report to be presented at the upcoming meeting of the American Society for Radiation Oncology (ASTRO) offers 5-year outcome data from a trial comparing conventional intensity-modulated radiation therapy (IMRT) to the more recently developed hypofractionated IMRT for men with localized prostate cancer.

A matched, case-control study of EBRT + PBRT vs brachytherapy

It would be all too easy to get the idea — from the title and abstract of a recently published study — that proton beam radiation therapy (PBRT) was more effective than permanent seed brachytherapy in the treatment of men with low- and some intermediate-risk prostate cancers. This would be a very inappropriate conclusion.

5-year brachytherapy outcomes vs. predicted surgical outcomes

As an adjunct to the 12-year outcome data provided in the immediately preceding report come data from Canada that compare actual 5-year brachytherapy outcome data to predicted 5-year surgical outcome data for the same patients.

Quality of life after first-line treatment: a prospective, comparative study

Data to be published in the May 2010 issue of the Journal of Urology are going to make a lot of urologists rather less than happy about the implications for the use of radical prostatectomy as first-line treatment for prostate cancer.

Surgery vs. radiotherapy as first-line treatment: an Italian perspective

An Italian study has reported data from a retrospective analysis of outcomes after radical surgery and external beam radiation therapy (EBRT) + androgen deprivation therapy (ADT) in first-line treatment of two, pre-treatment-defined, concurrently treated, high-risk patient populations, all treated at a single institution between January 2003 and December 2007.

First-line therapy for localized prostate cancer: outcomes and HRQOL

The decisions patients and their doctors make about which treatment to select as first-line therapy for localized prostate cancer are commonly based on perceptions and expectations about the side effects of these treatments, as well as on the curative potential of the therapy.

Follow

Get every new post delivered to your Inbox.

Join 269 other followers